We are live on ! Find out more
PGNX

Progenics Pharmaceuticals Inc
PGNX

Delisted

PGNX was delisted on the 19th of June, 2020.

Back to rankings

115 hedge funds and large institutions have $380M invested in Progenics Pharmaceuticals Inc in 2016 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 34 increasing their positions, 34 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

71% more first-time investments, than exits

New positions opened: 29 | Existing positions closed: 17

53% more capital invested

Capital invested by funds: $249M → $380M (+$131M)

44% more call options, than puts

Call options by funds: $1.47M | Put options by funds: $1.02M

11% more funds holding

Funds holding: 104 → 115 (+11)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 34

Holders
115
Holders Change
+11
Holders Change %
+10.58%
% of All Funds
3.07%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
29
Increased
34
Reduced
34
Closed
17
Calls
$1.47M
Puts
$1.02M
Net Calls
+$450K
Net Calls Change
+$2.59M

Top Buyers

Rank Fund Capital Flow
1
PFC
Phocas Financial Corp
California
+$5.71M
2
Goldman Sachs
Goldman Sachs
New York
+$5.38M
3
State Street
State Street
Massachusetts
+$3.36M
4
PWAM
Park West Asset Management
California
+$3.29M
5
HP
HealthInvest Partners
Sweden
+$1.69M

Top Sellers

Rank Fund Capital Flow
1
Tudor Investment Corp
Tudor Investment Corp
Connecticut
-$12.4M
2
Federated Hermes
Federated Hermes
Pennsylvania
-$3.6M
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
-$2.08M
4
BBA
Baker Bros. Advisors
New York
-$1.93M
5
RA
Royce & Associates
New York
-$1.12M
Name Holding Trade Value Shares
Change 		Change in
Stake
Tudor Investment Corp
26
Tudor Investment Corp
Connecticut
$1.82M -$12.4M -2,054,575 -88%
HP
27
HealthInvest Partners
Sweden
$1.77M +$1.69M +280,000 New
BIM
28
BlackRock Investment Management
Delaware
$1.73M +$74.7K +12,359 +5%
Dimensional Fund Advisors
29
Dimensional Fund Advisors
Texas
$1.64M -$2.08M -344,397 -57%
BA
30
BKS Advisors
Michigan
$1.54M -$60.5K -10,000 -4%
Allianz Asset Management
31
Allianz Asset Management
Germany
$1.4M +$1.34M +221,644 New
New York State Common Retirement Fund
32
New York State Common Retirement Fund
New York
$1.32M +$348K +57,490 +38%
California Public Employees Retirement System
33
California Public Employees Retirement System
California
$1.2M -$78K -12,900 -6%
CCM
34
Cadence Capital Management
Massachusetts
$1.19M -$26.5K -4,376 -2%
TI
35
Turner Investments
Pennsylvania
$1.12M +$303K +50,080 +39%
California State Teachers Retirement System (CalSTRS)
36
California State Teachers Retirement System (CalSTRS)
California
$931K +$12.1K +2,000 +1%
EI
37
EAM Investors
California
$917K +$876K +144,902 New
VEA
38
Virtus ETF Advisers
New York
$857K +$103K +17,055 +14%
EA
39
Emerald Acquisition
Washington
$778K +$344K +56,934 +86%
Citadel Advisors
40
Citadel Advisors
Florida
$751K +$718K +118,716 New
Swiss National Bank
41
Swiss National Bank
Switzerland
$732K – – –
SC
42
Searle & Co
Connecticut
$726K +$635K +105,000 New
TA
43
Teachers Advisors
New York
$691K – – –
AllianceBernstein
44
AllianceBernstein
Tennessee
$690K – – –
Fisher Asset Management
45
Fisher Asset Management
Washington
$682K -$198K -32,698 -23%
SAMC
46
Shinko Asset Management Company
Japan
$682K -$197K -32,528 -23%
CS
47
Credit Suisse
Switzerland
$612K +$81K +13,403 +16%
RhumbLine Advisers
48
RhumbLine Advisers
Massachusetts
$465K -$45.1K -7,465 -9%
Wells Fargo
49
Wells Fargo
California
$464K +$2.18K +360 +0.5%
Creative Planning
50
Creative Planning
Kansas
$462K +$423K +70,000 +2,333%
1
2
3 4 5

PGNX Hedge Fund Activity: Q3 2016 in Review

115 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Progenics Pharmaceuticals Inc (PGNX) for Q3 2016, worth a combined $380M — up 53% from $249M a quarter earlier.

Buyers outnumbered sellers: 29 funds opened new PGNX positions and 17 closed out — a net gain of 12 holders — while 34 added to existing stakes and 34 trimmed.

The largest buyer was Phocas Financial Corp, adding an estimated $5.71M. The largest seller was Tudor Investment Corp, cutting an estimated $12.4M.

  • 115 institutional investors held Progenics Pharmaceuticals Inc (PGNX) as of Q3 2016, up from 104 in Q2 2016.
  • Funds reported $380M of Progenics Pharmaceuticals Inc stock for Q3 2016, up 53% quarter-over-quarter.
  • 29 funds opened new Progenics Pharmaceuticals Inc positions in Q3 2016 and 17 closed out, a net change of +12 holders.
  • The largest Progenics Pharmaceuticals Inc buyer in Q3 2016 was Phocas Financial Corp, an estimated $5.71M added.
  • The largest Progenics Pharmaceuticals Inc seller in Q3 2016 was Tudor Investment Corp, an estimated $12.4M sold.

Based on aggregated 13F filings for Q3 2016.